Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: A retrospective study of 167 cases

Germán Campuzano-Zuluaga, Maureen Cioffi-Lavina, Izidore Lossos, Jennifer Chapman-Fredricks

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Previous studies have suggested that CD30 may be expressed in diffuse large B-cell lymphomas (DLBCLs). However, the prevalence of CD30 + DLBCLs and extent of CD30 expression within an individual tumor have not been fully evaluated. The aim of this study was to determine the frequency and extent of CD30 expression in DLBCLs, and explore possible relationships between CD30 expression and clinical and biologic variables. We retrospectively identified and analyzed 167 cases of CD30 + DLBCLs from our pathology archive. Twenty-one percent (95% confidence interval [CI]: 14.8-27.1%) of these cases expressed CD30, and in 52% of them CD30 was positive in > 80% of tumor cells. CD30 expression was more frequent in DLBCLs with non-germinal center origin phenotype, BCL2 + DLBCLs and in patients ≤ 47 years old. There was significant interaction of BCL2 expression with age and subtype of DLBCL. A multivariate analysis performed in BCL2 + DLBCLs showed a higher frequency of CD30 + cases in non-germinal center DLBCLs (odds ratio [OR]: 6.5, 95% CI: 1.1-36.5) and in patients ≤ 47 years old (OR: 6.9, 95% CI: 1.5-29.5). These associations could suggest a common biologic pathogenesis. The effectiveness of anti-CD30 drugs in other lymphomas opens the possibility for their use in patients with CD30 + DLBCLs.

Original languageEnglish
Pages (from-to)2405-2411
Number of pages7
JournalLeukemia and Lymphoma
Volume54
Issue number11
DOIs
StatePublished - Oct 21 2013

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Biological Factors
Retrospective Studies
Confidence Intervals
Odds Ratio
Lymphoma
Neoplasms
Multivariate Analysis
Pathology
Phenotype

Keywords

  • Brentuximab vedotin
  • CD30
  • Diffuse large B-cell lymphoma
  • Lymphoma and Hodgkin disease

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors : A retrospective study of 167 cases. / Campuzano-Zuluaga, Germán; Cioffi-Lavina, Maureen; Lossos, Izidore; Chapman-Fredricks, Jennifer.

In: Leukemia and Lymphoma, Vol. 54, No. 11, 21.10.2013, p. 2405-2411.

Research output: Contribution to journalArticle

@article{d81ef49956c94d55896093b8a1b62fb0,
title = "Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: A retrospective study of 167 cases",
abstract = "Previous studies have suggested that CD30 may be expressed in diffuse large B-cell lymphomas (DLBCLs). However, the prevalence of CD30 + DLBCLs and extent of CD30 expression within an individual tumor have not been fully evaluated. The aim of this study was to determine the frequency and extent of CD30 expression in DLBCLs, and explore possible relationships between CD30 expression and clinical and biologic variables. We retrospectively identified and analyzed 167 cases of CD30 + DLBCLs from our pathology archive. Twenty-one percent (95{\%} confidence interval [CI]: 14.8-27.1{\%}) of these cases expressed CD30, and in 52{\%} of them CD30 was positive in > 80{\%} of tumor cells. CD30 expression was more frequent in DLBCLs with non-germinal center origin phenotype, BCL2 + DLBCLs and in patients ≤ 47 years old. There was significant interaction of BCL2 expression with age and subtype of DLBCL. A multivariate analysis performed in BCL2 + DLBCLs showed a higher frequency of CD30 + cases in non-germinal center DLBCLs (odds ratio [OR]: 6.5, 95{\%} CI: 1.1-36.5) and in patients ≤ 47 years old (OR: 6.9, 95{\%} CI: 1.5-29.5). These associations could suggest a common biologic pathogenesis. The effectiveness of anti-CD30 drugs in other lymphomas opens the possibility for their use in patients with CD30 + DLBCLs.",
keywords = "Brentuximab vedotin, CD30, Diffuse large B-cell lymphoma, Lymphoma and Hodgkin disease",
author = "Germ{\'a}n Campuzano-Zuluaga and Maureen Cioffi-Lavina and Izidore Lossos and Jennifer Chapman-Fredricks",
year = "2013",
month = "10",
day = "21",
doi = "10.3109/10428194.2013.778407",
language = "English",
volume = "54",
pages = "2405--2411",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors

T2 - A retrospective study of 167 cases

AU - Campuzano-Zuluaga, Germán

AU - Cioffi-Lavina, Maureen

AU - Lossos, Izidore

AU - Chapman-Fredricks, Jennifer

PY - 2013/10/21

Y1 - 2013/10/21

N2 - Previous studies have suggested that CD30 may be expressed in diffuse large B-cell lymphomas (DLBCLs). However, the prevalence of CD30 + DLBCLs and extent of CD30 expression within an individual tumor have not been fully evaluated. The aim of this study was to determine the frequency and extent of CD30 expression in DLBCLs, and explore possible relationships between CD30 expression and clinical and biologic variables. We retrospectively identified and analyzed 167 cases of CD30 + DLBCLs from our pathology archive. Twenty-one percent (95% confidence interval [CI]: 14.8-27.1%) of these cases expressed CD30, and in 52% of them CD30 was positive in > 80% of tumor cells. CD30 expression was more frequent in DLBCLs with non-germinal center origin phenotype, BCL2 + DLBCLs and in patients ≤ 47 years old. There was significant interaction of BCL2 expression with age and subtype of DLBCL. A multivariate analysis performed in BCL2 + DLBCLs showed a higher frequency of CD30 + cases in non-germinal center DLBCLs (odds ratio [OR]: 6.5, 95% CI: 1.1-36.5) and in patients ≤ 47 years old (OR: 6.9, 95% CI: 1.5-29.5). These associations could suggest a common biologic pathogenesis. The effectiveness of anti-CD30 drugs in other lymphomas opens the possibility for their use in patients with CD30 + DLBCLs.

AB - Previous studies have suggested that CD30 may be expressed in diffuse large B-cell lymphomas (DLBCLs). However, the prevalence of CD30 + DLBCLs and extent of CD30 expression within an individual tumor have not been fully evaluated. The aim of this study was to determine the frequency and extent of CD30 expression in DLBCLs, and explore possible relationships between CD30 expression and clinical and biologic variables. We retrospectively identified and analyzed 167 cases of CD30 + DLBCLs from our pathology archive. Twenty-one percent (95% confidence interval [CI]: 14.8-27.1%) of these cases expressed CD30, and in 52% of them CD30 was positive in > 80% of tumor cells. CD30 expression was more frequent in DLBCLs with non-germinal center origin phenotype, BCL2 + DLBCLs and in patients ≤ 47 years old. There was significant interaction of BCL2 expression with age and subtype of DLBCL. A multivariate analysis performed in BCL2 + DLBCLs showed a higher frequency of CD30 + cases in non-germinal center DLBCLs (odds ratio [OR]: 6.5, 95% CI: 1.1-36.5) and in patients ≤ 47 years old (OR: 6.9, 95% CI: 1.5-29.5). These associations could suggest a common biologic pathogenesis. The effectiveness of anti-CD30 drugs in other lymphomas opens the possibility for their use in patients with CD30 + DLBCLs.

KW - Brentuximab vedotin

KW - CD30

KW - Diffuse large B-cell lymphoma

KW - Lymphoma and Hodgkin disease

UR - http://www.scopus.com/inward/record.url?scp=84885592678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885592678&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.778407

DO - 10.3109/10428194.2013.778407

M3 - Article

C2 - 23432725

AN - SCOPUS:84885592678

VL - 54

SP - 2405

EP - 2411

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 11

ER -